Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults.
To assess the reactogenicity and immunogenicity of the Biken acellular pertussis vaccine (Pa) following administration of a single vaccine dose to young adults with or without a history of prior pertussis immunization, 104 healthy, male and female adults without primary pertussis immunization were enrolled in Mainz (former West Germany; "not previously pertussis vaccinated", N-PPV-group); in parallel, 103 adults with a history of having received >/=four doses of a combined diphtheria-, tetanus-toxoid, whole-cell pertussis vaccine (DTwP) were enrolled in Magdeburg (former East Germany; "previously pertussis-vaccinated", PPV-group). Large areas of redness (>20 mm) were seen in 2.9%/1.0% of subjects in the N-PPV/PPV group, and a large swelling was seen in 6.8%/1.0%, respectively. As compared to baseline concentrations, antibody titers to PT and FHA were 77-(PT)/64-(FHA) (N-PPV group) and 94-(PT)/126-(FHA) fold (PPV group) higher. The study vaccine was safe and induced infrequent and mostly mild, local and general symptoms that all resolved spontaneously; it was highly immunogenic in adults, whether or not they had been previously vaccinated with DTwP.
Schmitt
H J
HJ
Pediatric Infectious Diseases, Department of Pediatrics, Christian-Albrechts-Universität zu Kiel, Schwanenweg 20, 24105 Kiel, Germany. hgschmitt@pediatrics.uni-kiel.de
Mohnike
K
K
Zepp
F
F
Herden
P
P
Hosbach
P
P
D018829:Adhesins, Bacterial / Q000008:administration & dosage; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D001886:Bordetella pertussis / Q000276:immunology; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage; D005260:Female; D006388:Hemagglutinins / Q000008:administration & dosage; D006801:Humans; D008297:Male; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D012449:Safety; D014121:Toxoids / Q000008:administration & dosage; D022282:Vaccines, Acellular / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D010566:Virulence Factors, Bordetella
D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D014121:Toxoids; D022282:Vaccines, Acellular; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; C051093:pertussis toxoid